glp-1 for addiction treatment IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1s Like Ozempic May Be

When assessing WL post-bariatric surgery and WR thereafter before initiation of therapy, our analysis found no significant differences between the GLP-1RAs and placebo groups, with (SMD = 0.23, 95% CI 0.36 to 0.81) for WL and SMD = 0.33, 95% CI 0.11 to 0.77) for WR, respectively (Supplementary Figs

GLP-1-associated weight loss may also coincide with clinically relevant lean-mass reductions, potentially influencing tissue quality and contouring strategy

Wu T, Yang M, Xu H, et al

Rossing P, Agarwal R, Anker SD et al (2023) Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use

Anesthesiologists need to confirm your stomach is empty before intubation to keep your airway safe

Within the main application segment of the GLP-1 Receptor Agonist Market, two critical sub-segments emerge: obesity and cardiovascular diseases